DanielSullivanMD

PubMed

• Lenalidomide-based response-adapted therapy for older adults without high risk myeloma.
  Baz, R.,Naqvi, SMH.,Lee, J. H.,Brayer, J.,Hillgruber, N.,Fridley, B. L.,Shain, K. H.,Sullivan, D. M.,Alsina, M.> ;Br. J. Haematol.. 2018 Dec 15
• A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer.
  Soliman, H.,Khambati, F.,Han, H. S.,Ismail-Khan, R.,Bui, M. M.,Sullivan, D. M.,Antonia, S.> ;Oncotarget. 2018 Mar 09
• XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human ...
  Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM> ;Oncotarget. 2016-10-28
• Imaging biomarker roadmap for cancer studies.
  O'Connor JPB, Aboagye EO, Adams JE, Aerts HJWL, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Co...> ;Nat Rev Clin Oncol. 2016-10-11
• Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
  Joel G. Turner, Jana L. Dawson, Steven Grant, Kenneth H. Shain, William S. Dalton, Yun Dai, Mark B. Meads, Rachid Baz, Michael Kauffman, Sharon Shacham, Daniel M. Sull...> ;Journal of Hematology & Oncology. 2016 Aug 24
• Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.
  Rollison DE, Komrokji R, Lee J, Hampras S, Fulp W, Fisher K, Baz R, Nishihori T, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Sullivan D, Alsina M, Dalton W, Shain KH> ;Leuk. Lymphoma. 2016-07-18
• Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
  Baz RC, Martin TG, Lin H, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S> ;Blood. 2016-05-26
• A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
  Beata Holkova, Adriana Zingone, Maciej Kmieciak, Prithviraj Bose, Ashraf Badros, Peter M. Voorhees, Rachid Baz, Neha Korde, Hui-Yi Lin, Jin-Qiu Chen, Michelle A. Herrm...> ;Clinical Cancer Research. 2016 Mar 1
• Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
  Seymour, L., Groshen, S., Rosner, G. L., Sullivan, D. M., Spriggs, D. R., Reeves, S., Gravell, A., Ivy, S. P., Ratain, M. J.> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Nov 15
• Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.
  Amit Mahipal, Aaron Cleveland Denson, Benjamin Djulbegovic, Richard Lush, Ambuj Kumar, Tzu Hua Juan, Michael J. Schell, Daniel M. Sullivan> ;Cancer Control. 2015 Apr 1
• Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
  Smith, D. C.,Kalebic, T.,Infante, J. R.,Siu, L. L.,Sullivan, D.,Vlahovic, G.,Kauh, J. S.,Gao, F.,Berger, A. J.,Tirrell, S.,Gupta, N.,Di Bacco, A.,Berg, D.,Liu, G.,Lin,...> ;Invest New Drugs. 2015 Mar 18
• Canonical Wnt Pathway Inhibitor ICG-001 Induces Cytotoxicity of Multiple Myeloma Cells in Wnt-Independent Manner
  Eileen R. Grigson, Maria Ozerova, Alexandra Pisklakova, Hao Liu, Daniel M. Sullivan, Yulia Nefedova> ;PLOS ONE. 2015 Jan 30
• An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.
  Nishihori, T.,Baz, R.,Shain, K.,Kim, J.,Ochoa-Bayona, J. L.,Yue, B.,Sullivan, D.,Dalton, W.,Alsina, M.> ;Eur. J. Haematol.. 2015 Jan 21
• A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the ...
  Brana, I.,Berger, R.,Golan, T.,Haluska, P.,Edenfield, J.,Fiorica, J.,Stephenson, J.,Martin, L. P.,Westin, S.,Hanjani, P.,Jones, M. B.,Almhanna, K.,Wenham, R. M.,Sulliv...> ;Br. J. Cancer. 2014 Oct 08
• Phase I Trial of Bortezomib and "Non-Hybrid "(Bolus) Infusion Schedule of Alvocidib (Flavopiridol) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms.
  Holkova, B.,Kmieciak, M.,Perkins, E. B.,Bose, P.,Baz, R.,Roodman, G. D.,Stuart, R. K.,Ramakrishnan, V.,Wan, W.,Peer, C. J.,Dawson, J. L.,Kang, L.,Honeycutt, C.,Tombes,...> ;Clin. Cancer Res.. 2014 Sep 25
• 18 citations
  Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents
  Joel G. Turner, Jana L. Dawson, Christopher L. Cubitt, Rachid Baz, Daniel M. Sullivan> ;Seminars in Cancer Biology. 2014 Aug 1
• Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
  Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, Tolcher AW, Mi...> ;J Hematol Oncol. 2014-01-03
• Phase II study of pegylated liposomal doxorubicin, low‐dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
  Rachid Baz, Kenneth H. Shain, Mohamad A. Hussein, Ji-Hyun Lee, Daniel M. Sullivan, Elizabeth Finley Oliver, Lisa A Nardelli, Lisa A. Nodzon, Xiuhua Zhao, Jose L. Ochoa...> ;American Journal of Hematology. 2014 Jan 1
• A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
  Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, ...> ;Breast Cancer Res.. 2013-11-19
• MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines.
  Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S, Malafa M> ;Cancer Biol. Ther.. 2013-10-01
• Sequence of novel agents in multiple myeloma: An instrumental variable analysis.
  Baz, R.,Miladinovic, B.,Patel, A.,Ho, V. Q.,Shain, K. H.,Alsina, M.,Nishihori, T.,Ochoa-Bayona, J. L.,Sullivan, D. M.,Dalton, W. S.,Djulbegovic, B.> ;Leuk. Res.. 2013 Sep
• The imaging viewpoint: how imaging affects determination of progression-free survival.
  Sullivan DC, Schwartz LH, Zhao B> ;Clin. Cancer Res.. 2013-05-15
• Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
  Nishihori, T.,Ochoa-Bayona, J. L.,Kim, J.,Pidala, J.,Shain, K.,Baz, R.,Sullivan, D.,Jim, H. S.,Anasetti, C.,Alsina, M.> ;Bone Marrow Transplant.. 2013 Sep
• Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
  Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Na...> ;Blood. 2013-03-14
• Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicente...
  Jacobsen PB, Wells KJ, Meade CD, Quinn GP, Lee J, Fulp WJ, Gray JE, Baz RC, Springett GM, Levine RM, Markham M, Schreiber FJ, Cartwright TH, Burke JM, Siegel RD, Malaf...> ;J. Clin. Oncol.. 2012-07-10
• Join now to see all

Journal Articles

• An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma  
  Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M, Eur J Haematol, 1/20/2015
• Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRAC-mutant ovarian cancer  
  Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ, Szabo P, Youn A, Chen AP, Ji J, Allen DE, Lih C-J, Mehaffey MG, Wal..., Clin Cancer Res, 1/1/2015
• Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer  
  Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A, Mol Cancer Ther, 1/1/2015
• A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors  
  Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S, Oncotarget, 1/30/2014
• Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers  
  Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos K, Olmos D, Baird R, Delgado L, Tetteh E, Beckman R, Lupinacci L, Riisnaes R, Decordova S, Heaton..., Clin Cancer Res, 1/15/2014
• Phase I trial of bortezomib (PS-341; NSC 681239) and "non-hybrid"(bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refrac...  
  Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wig..., Clin Cancer Res, 1/15/2014
• A parallel-arm phase I trial of the humanized anti-IGF-1R antibody Dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor Ridaforolimus, or the ...  
  Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin L, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gu..., Br J Cancer, 1/11/2014
• Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors  
  Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, Tolcher AW, Mi..., J Hematol Oncol, 1/3/2014
• Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma  
  Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Oliver EF, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M, Am J Hematol, 1/1/2014
• Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents  
  Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM, Semin Cancer Biol, 1/1/2014
• A phase I study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and Trastuzumab in patients with HER2-positive solid tumors  
  Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, ..., Breast Cancer Res, 1/19/2013
• MK-2206, an AKT inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines  
  Almhanna K, Cubitt CL, Zhang S, Kazim S, Sullivan D, Sebti S, Malafa M, Cancer Biol Ther, 1/5/2013
• Implementation of Timeline Reforms Significantly Speeds Up Initiation of NCI-sponsored Trials  
  Abrams JS, Mooney M, Zwiebel J, Korn E, Friedman S, Finnigan S, Schettino P, Denicoff A, Kruhm M, Montello M, Misra R, Ansher S, DiPiazza K, Souhan E, Wickerham D, Gia..., J Natl Cancer Inst, 1/1/2013
• Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma  
  Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M, Bone Marrow Transplant, 1/1/2013
• Phase I study of pomalidomide MTD, safety and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib  
  Richardson P, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nar..., Blood, 1/1/2013
• Sequence of Novel Agents in Multiple Myeloma: An Instrumental Variable Analysis  
  Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B, Leuk Res, 1/1/2013
• CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vivo and ex vivo  
  Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM, J Cancer, 1/1/2013
• Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation  
  Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL, Biol Blood Marrow Transplant, 1/1/2012
• Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma  
  Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J,..., Br J Haematol, 1/1/2012
• A phase II study of RO4929097 in metastatic colorectal cancer  
  Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D, Eur J Cancer, 1/1/2012
• Nuclear export of proteins and drug resistance in cancer  
  Turner JG, Dawson J, Sullivan DM, Biochem Pharmacol, 1/1/2012
• A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer  
  Lush R, Patnaik A, Sullivan D, Papadopoulos K, Trucksis M, McCrea J, Cerchio K, Li X, Stroh M, Selverian D, Orford K, Ebbinghaus S, Agrawal N, Iwamoto M, Wagner JA, To..., Cancer Chemother Pharmacol, 1/1/2012
• Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy  
  Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E, Gabrilovich DI, Cancer Res, 1/1/2012
• The creation of an integrated health-information platform: building the framework to support personalized medicine  
  Wenham RM, Sullivan DM, Hulse M, Jacobsen PB, Dalton WS, Personalized Medicine, 1/1/2012
• Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma  
  Chen F, Pisklakova A, Li M, Baz R, Sullivan DM, Nefedova Y, Cell Oncol (Dordr), 1/1/2011
• Join now to see all

Books/Book Chapters

• Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Cancer Growth and Progression 13 
  Chapter: Topoisomerase I Inhibitors-The Camptothecins. 
  Newton M, Wetzstein G, Sullivan DEditors: Minez BR.Springer Science+Business Media, New York2011
• Methods in Molecular Biology, Vol. 95; DNA Topoisomerase Protocols, Part II: Enzymology and Drugs 
  Chapter: DNA Topoisomerase II Catalyzed DNA Decatenation. 
  Haldane A, Sullivan DMEditors: Osheroff N, Bjornsti MA.Humana Press Inc., Totowa, NJ2001
• Hematology: Basic Principles and Practice 
  Chapter: Pharmacology and Molecular Mechanism of Action or Resistance of Antineoplastic Agents: Current Status and Future Potential. 
  Page 885 - 938Bhalla K, Gerson S, Grant S, Sullivan DMEditors: Hoffman R, Benz Jr EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P.Churchill Livingstone, New York2000
• Diagnostik and Therapie des Mammakarzinoms 
  Chapter: High dose chemotherapy for the treatment of high risk, early stage breast cancer: analysis of risk factors. 
  Fields KK, Perkins J, Goldstein S, Elfenbein G, Saez R, Sullivan DM, Partyka J, Kronish LEditors: Untech M, Konecny G, Sittek H.Verlag, Munchen. W. Zuckeschwerdt1998
• Decision Making in Oncology: Evidence Based Management 
  Djulbegovic B, Sullivan, DMChurchill Livingstone Inc., New York1997
• Decision Making in Oncology: Evidence Based Management 
  Chapter: Breast Cancer. 
  Page 253 - 265Fields KK, Goldstein SC, Clark RA, Sullivan DMEditors: Djulbegovic B, Sullivan DM.Churchill Livingstone Inc., New York1997
• Molecular and Clinical Advances in Anticancer Drug Resistance 
  Chapter: Resistance to Inhibitors of DNA Topoisomerases. 
  Page 57 - 99Sullivan DM, Ross WEEditors: Ozols RF.Kluwer Academic Publishers, Boston, MA1991
• Resistance to Antineoplastic Drugs 
  Chapter: Topoisomerase II Mediated Mechanisms of Drug Resistance. 
  Page 281 - 292Sullivan DM, Chow K-C, Ross WEEditors: Kessel D.CRC Press, Boca Raton, FL1989
• Anticancer Drugs 
  Chapter: Pathways of Resistance to Topoisomerase II Inhibitors. 
  Page 93 - 101Ross WE, Lock RB, Chow KC, Latham M, Sullivan DMEditors: Tapiero J, Robert J, Lampidis TJ.Colloque INSERM/John Libbey Eurotex Ltd1989
• Important Advances in Oncology 
  Chapter: Altered Function of DNA Topoisomerases as a Basis for Antineoplastic Drug Action. 
  Page 65 - 81Ross WE, Sullivan DM, Chow K-CEditors: DeVita Jr VT, Hellman S, Rosenberg SA.J.B. Lippincott Company, Philadelphia, PA1988
• First Conference on DNA Topoisomerases in Cancer Chemotherapy 
  Chapter: The Role of Proliferation in Determining Sensitivity to Topoisomerase II-Active Chemotherapy Agents. 
  Page 73 - 78Sullivan DM, Chow K-C, Glisson BS, Ross WEEditors: Potmesil M, Ross WE.1987
• First Conference on DNA Topoisomerases in Cancer Chemotherapy 
  Chapter: Mediation of Multi-Drug Resistance in a Chinese Hamster Ovary Cell Line by a Mutant Type II Topoisomerase. 
  Page 89 - 93Glisson BS, Sullivan DM, Gupta R, Ross WEEditors: Potmesil M, Ross WE.1987
• Biochemistry of S-Adenosylmethionine and Related Compounds 
  Hoffman JL, Sullivan DMEditors: Usdin E, Borchardt RT, Creveling, CR.Macmillan, London1982
• Join now to see all

Abstracts/Posters

• The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
  Daniel M Sullivan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Study of Sunitinib Malate (SM) in Subjects With Metastatic and/or Surgically Unresectable non-GIST Soft Tissue Sarcomas.
  Vigil CE, Chiappori AA, Williams CA, Shrager HH, Murray BL, Letson DG, Sullivan DM, Garrett CR, D'Amato GZ, Agresta SV, ASCO Annual Meeting Proceedings, 1/1/2008
• Benefits (Survival) and Risks (30 Days Mortality) of Phase I Trials in Oncology.
  Djulbegovic B, Moreno C, Kumar A, Lush R, Munster PN, Daud AI, Garrett CR, Simon GR, Lancet JE, Sullivan DM, Phase I Program Physician and Nurses, ASCO Annual Meeting Proceedings, 1/1/2008
• Topoisomerase II Alpha Trafficking Between the Nucleus and Cytoplasm Is Controlled by Phosphorylation of a Casein Kinase II Site in the Carboxy-Terminal Domain.
  Turner JG, Gump J, Fang B, Koomen J, Sullivan DM, AACR Annual Meeting, 1/1/2008
• Combined Dasatinib and Tricribine Treatment Synergistically Inhibits the Growth of Sarcoma Cells.
  Cubitt CL, Gump J, Fielding EN, Menth JL, Cheng J, Sebti SM, Sullivan DM, AACR Annual Meeting, 1/1/2008
• Administration of Rituximab Is Feasible and Does Not Affect Engraftment of Allograft Recipients With Advanced CD20+ Malignancies.
  Kharfan-Dabaja MA, Tate C, Perkins J, Fernandez HF, Field T, Ayala E, Perez L, Raychaudhuri J, Alsina M, Sullivan D, Brand L, Poling W, Anasetti M, Bllod, ASH Annual Meeting, 1/1/2007
• Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients 60 and >60 Years of Age With Multiple Myeloma (MM).
  Sullivan D, Alsina M, Anasetti C, Field T, Kharfan-Dabaja M, Fernandez H, Dalton W, Ayala E, Raychaudhuri J, Perez L, Perkins J, Schell M, McIsaac C, Maddox B, Gump J,..., Bllod, ASH Annual Meeting, 1/1/2007
• Phase I Study of Bortezomib (BTZ) Followed by High-Dose Melphalan (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) ...
  Alekshun T, McIsaac-Simonelli C, Kharfan-Dabaja M, Dalton W, Djulbegovic B, Fernandez H, Sullivan DM, Ayala E, Field TL, Garrett D, Janssen WE, Maddox B, Perez L, Kett..., Bllod, ASH Annual Meeting, 1/1/2007
• Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) After Pretransplant 5-Azacitidine.
  Field T, Alsina M, Ayala E, Fernandez H, Janssen W, Kharfan-Dabaja M, Lancet J, Melchert M, Raychaudhuri J, Sullivan D, List A, Anasetti C, Poling W, Perkins J, Bllod, ASH Annual Meeting, 1/1/2007
• Phase I Trial of a Sequence-Specific Combination of the HDAC Inhibitor Vorinostat (SAHA) Followed by Doxorubicin in Advanced Solid Tumor Malignancies.
  Daud A, Schmitt M, Marchion D, Bicaku E, Minton S, Egorin M, Zwiebel J, Chiappori A, Sullivan D, Munster P, ASCO Annual Meeting Proceedings, 1/1/2007
• Phase I Pharmacokinetic and Pharmacodynamic Study of the Inhibitor of Activation of AKT (p-Akt), Triciribine Phosphate Monohydrate (TCN-PM), in Solid Malignancies.
  Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Sullivan DM, Cheng JQ, Sebti SM, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 1/1/2007
• Phase I Trial of the Histone Deacetylase Inhibitor Valproic Acid with the Topoisomerase I Inhibitor, Karenitecin in Advanced Melanoma.
  Daud AI, Gump JL, Neuger A, DeConti RH, Bastien S, Mintz M, Hausheer FH, Lush R, Sullivan DM, Munster PN, NCI-AACR-EORTC, 1/1/2006
• Phase I Trial of CT-2106 (polyglutamated camptothecin) Administered Weekly in Patients (pts) With Advanced Solid Tumors.
  Daud AI, Garrett C, Simon GR, Munster P, Sullivan D, Stromatt S, Allevi C, Berareggi B, ASCO Annual Meeting, 1/1/2006
• Pre-Transplant 5-Azacitidine (Vidaza) May Improve Outcome of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients With Myelodysplastic Syndrome (MDS).
  Field T, Perkins J, Alsina M, Ayala E, Fernandez HF, Janssen W, Kharfan-Dabaja M, Lancet J, Perez L, Sullivan D, List A, Anasetti C, ASH Annual Meeting, 1/1/2006
• Phase I Trial of a Sequence-specific Combination of the HDAC Inhibitor, Valproic Acid (VPA), and the Topoisomerase II Inhibitor, Epirubicin, in Advanced Solid Tumors: ...
  Munster PN, Marchion DC, Bicaku E, Schmitt ML, Padilla B, Stauffer P, Garrett CR, Chiapporo A, Sullivan DM, Daud AI, ASCO Annual Meeting, 1/1/2006
• Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM).
  Stewart K, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris III H, Karol M, Zannikos P, Reece DE, ASH Annual Meeting, 1/1/2006
• CRM1 Knockdown by Ratjadone C, Leptomycin B, and siRNA to CRM1, Enhance Sensitivity of Human Multiple Myeloma Cells to Topoisomerase II Inhibitors.
  Turner JG, Marchion DC, Seijo ER, Emmons MF, Hazelhurst LA, Munster PN, Washausen P, Sullivan DM, AACR Annual Meeting Proceedings, 1/1/2006
• Is Cytoplasmic Localization of Topoisomerase I (topo I) a Mechanism of Resistance for Topo I Inhibitors? Results From an NCCN Sponsored Phase II Trial of Gemcitabine a...
  Moulder SL, Valkov N, Gump J, Munster P, Minton S, Horton J, Lacevic M, Rocha Lima C, Sullivan D, AACR Annual Meeting Proceedings, 1/1/2006
• PDGF-R Alpha Expression and Activation in Human Sarcoma.
  Windham CT, D'Amato GZ, Keschman EA, Mohapatra S, Burns AC, Sullivan D, Letson GD, Jove R, Pledger WJ, AACR Annual Meeting Proceedings, 1/1/2006
• Valproic Acid Sensitizes Human Melanoma Cells to Karenitecin in Vitro and in Vivo.
  Gump JL, Marchion DC, Bicaku E, Turner JG, Hausheer FH, Daud AI, Munster PN, Sullivan DM, AACR Annual Meeting Proceedings, 1/1/2006
• Phase I/II Study of Atrasentan (A) in Combination With Carboplatin (C) and Paclitaxel (P) in Chemonaive Patients (PTS) With Advanced Non-Small Cell Lung Cancer (NSCLC).
  Chiappori A, Haura E, Williams CC, Simon G, Antonia S, Cantor A, Burton MK, Lush R, Sullivan DM, Bepler G, ASCO Annual Meeting, 1/1/2005
• Phase II Study of Oxaliplatin, Capecitabine, and Irinotecan (OCI) in Patients (pts) With Previously Untreated Advanced Colorectal Cancer (CRC).
  Pavia OA, Cangiano J, Crisostomo R, Caceres W, Barranco E, Wright M, Antonia T, Antonia S, Sullivan D, Garrett C, ASCO Annual Meeting, 1/1/2005
• Nuclear and Cytoplasmic Topoisomerase II Alpha are Differentially Phosphorylated and Nuclear Export is Blocked by CRM1 Antisense Oligonucleotides.
  Turner JG, Gump J, Ferraro B, Sullivan DM, AACR Annual Meeting Proceedings, 1/1/2005
• Phase I Trial of the Histone Deacetylase Inhibitor, Valproic Acid and the Topoisomerase II Inhibitor, Epirubicin: A Clinical and Translational Study.
  Munster PN, Marchion DC, Bicaku E, Padilla B, Beam C, Mahany J, Lush R, Sullivan DM, Daud AI, ASCO Annual Meeting, 1/1/2005
• Pharmacokinetic and Pharmacodynamic Analysis of the HDAC Inhibitor, Valproic Acid in Combination With the Anthracycline, Epirubicin in Solid Tumor Malignancies.
  Munster PN, Marchion DC, Bicaku E, Schmitt M, Lush R, Sullivan DM, Daud AI, EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 1/1/2005
• Join now to see all

Lectures

• "XP01 and Nuclear Export Inhibitors in Multiple Myeloma and AML" 
  1/24/2015
• "Overcoming drug-resistance in multiple myeloma by XPO1 inhibitor combination therapy". 
  Barcelona, Spain - 1/18/2014
• The Impact of Precision Oncology on Clinical Trials: Solving the Puzzle. 
  The Westin O'Hare, Chicago - 1/9/2014
• "Accelerating Clinical Research Using the TCC Database and Biorepository" 
  Omaha, NE - 1/26/2013
• "Personalized Cancer Trials That Use the Total Cancer Care Database" 
  Toronto, Canada - 1/11/2013
• "Total Cancer Care and Biobanking: Current E-Advancements and Future Applications" 
  Hollywood, FL - 1/3/2013
• "Evolving Role of Total Cancer Care in Personalized Cancer Therapy in Myeloma" 
  San Juan, Puerto Rico - 1/22/2012
• "Molecularly Characterized Patient Pool" 
  Beijing, China - 1/20/2012
• "Personalized Clinical Trials That Use the Total Cancer Care Database" 
  Montreal, Quebec, Canada - 1/15/2012
• "Accelerating Clinical Research Using the TCC™ Database and Biorepository" 
  Hershey, PA - 1/8/2012
• "Experimental and Molecular Therapeutics: Novel Mechanisms of Drug Resistance" 
  Washington, DC - 1/1/2006
• "Cellular, Molecular, and Tumor Biology: Signaling and Therapeutics" 
  Orlando, FL - 1/27/2004
• "Emerging Cancer Treatment Modalities: From Research to Practice" 
  Copper Mountain, CO - 1/21/2004
• "Bioethical Considerations in Human Subject Research" 
  Clearwater, FL - 1/11/2004
• "Molecular Targets for Cancer Therapy: Third Biennial Meeting" 
  St. Petersburg, FL - 1/1/2004
• "Molecular Targets for Cancer Therapy: Second Biennial Meeting" 
  St. Petersburg, FL - 1/11/2002
• Join now to see all

Other

• Efficacy of Topoisomerase I and II Inhibitors in Combination with Standard Chemotherapeutic Agents (Ara-C and Daunorubicin) in the Management of Acute Myeloid Leukemia... 
  Saba HI, Sullivan DM, Loughran Jr TP, Moscinski LC, Sullivan PA, Morelli GA
  1/1/2003
• "Fractionation, kinetic properties, and inhibition by L-methionine analogs of rat liver and kidney methionine adenosyltransferase isozymes" 
  Sullivan DM, M.S. Thesis, University of Louisville
  1/1/1982